Public release date: 9-Oct-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, October 9, 2013Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Human Gene Therapy website.

Satiro Nakamura De Oliveira and coauthors from the David Geffen School of Medicine, University of California, Los Angeles and University of Texas MD Anderson Cancer Center, Houston, describe the gene transfer method they developed to deliver chimeric antigen receptors, or CARS, that direct the immune system to target tumor cells derived from B-lymphocytes.

In the article "Modification of Hematopoietic Stem/Progenitor Cells with CD19-specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy" the authors show that by packaging the CARS in human hematopoietic stem cells, the immunotherapeutic receptors will be produced in the bloodstream for a long period of time. This persistent expression should improve their effectiveness in the treatment of blood cancers such as leukemia and lymphoma.

"This study represents an interesting new direction for an approach that has generated substantial interest," says Dr. Wilson, Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

###

About the Journal

Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journal, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, new in 2013, publishes data relevant to the regulatory review and commercial development of cell and gene therapy products. Complete tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Go here to see the original:
Novel gene therapy enables persistent anti-tumor immune response

Recommendation and review posted by Bethany Smith

Employment after Spinal Cord Injury: How Do You Get There?
Visit our home page http://sci.washington.edu Getting back to work or into the work force for the first time after a spinal cord injury can seem out of reach...

By: UWSpinalCordInjury

Originally posted here:
Employment after Spinal Cord Injury: How Do You Get There? - Video

Recommendation and review posted by sam

Physician First Choice Stem Cell Therapy (888) 828-4575
http://stemcelltreatmentclinic.com Physician First Choice offers US Board Certified stem cell doctors providing treatment in both the US and Mexico. Treatmen...

By: USPainNetwork

See the original post here:
Physician First Choice Stem Cell Therapy (888) 828-4575 - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Hormonal Treatment
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

Read this article:
Cell Therapy - Hormonal Treatment - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Introduction
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

See original here:
Cell Therapy - Introduction - Video

Recommendation and review posted by Bethany Smith

SAN DIEGO--(BUSINESS WIRE)--

OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced positive preliminary animal data demonstrating the benefits of combining the companys ImmunoPulse with anti-CTLA4 and anti-PD1 antibodies.

Dr. Richard Heller, professor at Old Dominion University, summarized the initial results of this study at the Cancer Vaccines and Gene Therapy Meeting in Philadelphia, Pennsylvania. The study was conducted using a single tumor model where a total of forty mice (eight treatment groups) were treated with either ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both at varying concentrations. Safety and anti-tumor activity were assessed. Results indicate that all treatment groups showed 100% regression of treated lesions in all mice, and that no mice died as a result of toxicity from treatment. The results from this initial study demonstrate that ImmunoPulse in combination with anti-CTLA4 or anti-PD1 is safe, effective and does not have any contraindicated outcomes. Based on these positive results the company intends to continue testing combination approaches in more aggressive melanoma models that will support further evaluation of this approach in humans.

Results are encouraging and indicate that using gene electrotransfer to deliver plasmid IL-12 into tumors can be an effective and safe delivery tool. Additional studies are being conducted to demonstrate that the combination may lead to immune responses against distant untreated lesions in mice. We will investigate the anti-tumor response and plan to present these findings in the near future, commented Dr. Heller.

In addition, Dr. Adil Daud, principal investigator and co-director of melanoma research at the University of California San Francisco School of Medicine, reviewed previously presented data from OncoSecs Phase II melanoma program. In his presentation titled Gene Electrotransfer in Solid Tumors, Dr. Daud discussed that continual analysis of the data so far confirms signals demonstrated in the positive interim immune response data presented earlier in the year.

About the Sponsored Research Agreement with Old Dominion University for Combination Study in Melanoma

In June of 2013, OncoSec signed a Sponsored Research Agreement (SRA) withOld Dominion University(ODU) and the Frank Reidy Research Center for Bioelectrics. Under the agreement, OncoSec and the University agreed to collaborate on nonclinical research focused on developing new technology related to electroporation and delivery of different agents into solid tumors by electroporation. The first research experiment under the SRA was to evaluate the effects of ImmunoPulse in combination with Anti-CTLA4, Anti-PD1 and Anti-PDL-1 in a melanoma mouse model.

About OncoSec Medical Inc.

OncoSec Medical Inc. isa biopharmaceutical companydeveloping its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors.ImmunoPulse and NeoPulse therapiesaddress an unmet medical needandrepresenta potential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietaryuse of anelectroporation platform to enhancethedelivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent(NeoPulse). Treatment ofvarious solid cancersusing these targetedanti-cancer agentshas demonstratedselective destruction of cancerous cellswhile potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available athttp://www.oncosec.com/.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Originally posted here:
OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study

Recommendation and review posted by Bethany Smith

October 8, 2013

Lee Rannals for redOrbit.com Your Universe Online

Sunscreen not only helps prevent three types of skin cancer, it also shields a superhero gene that repairs sun-damaged skin.

Scientists performing the worlds first human study to assess the impact of sunscreen at the molecular level have confirmed that the skin protector provides 100 percent protection against all three-forms of skin cancer, including basal cell carcinoma, squamous cell carcinoma, and malignant melanoma.

Researchers writing in the journal Pigment Cell & Melanoma Research looked at the impact of sunlight on human skin, both with and without sunscreen. They found no evidence of UV-induced skin damage when of sunscreen had been properly applied to an exposed area.

The team determined that not only does sunscreen provide 100 percent protection against the skin cancers, but it also shielded the p53 gene, which works to prevent cancer.

As soon as our skin becomes sun damaged, the p53 gene goes to work repairing that damage and thereby preventing skin cancer occurring, Lead researcher Dr. Elke Hacker, from Queensland University of Technologys AusSun Research Lab, said in a press release. But over time if skin is burnt regularly the p53 gene mutates and can no longer do the job it was intended for it no longer repairs sun damaged skin and without this protection skin cancers are far more likely to occur.

The study involved 57 people undergoing a series of skin biopsies to determine molecular changes to the skin before and after UV exposure and with and without sunscreen. First, the team took small skin biopsies of peoples unexposed skin. After this, they exposed two skin sites to a mild burning dose of UV light. One site was covered with sunscreen, while the other was not.

After 24 hours, we took another set of biopsies and compared the skin samples, Hacker said. What we found was that, after 24 hours, where the sunscreen had been applied there were no DNA changes to the skin and no impact on the p53 gene.

She said that this study looked beyond the redness of skin to determine whether sunscreen helps prevent molecular changes that have been linked to skin cancers.

Follow this link:
Sunscreen Helps Protect 'Superhero' Gene, Prevents Skin Cancer

Recommendation and review posted by Bethany Smith

Oct. 8, 2013 ext time your kids complain about putting on sunscreen, tell them this: Sunscreen shields a superhero gene that protects them from getting cancer.

It is widely accepted that sunscreen stops you from getting burnt but to date there has been academic debate about the effectiveness of sunscreen in preventing skin cancers.

Now QUT has undertaken a world-first human study to assess the impact of sunscreen at the molecular level.

Researchers found sunscreen provides 100 per cent protection against all three forms of skin cancer: BCC (basal cell carcinoma); SCC (squamous cell carcinoma); and malignant melanoma.

Lead researcher Dr Elke Hacker, from QUT's AusSun Research Lab, said sunscreen not only provided 100 per cent protection against the damage that can lead to skin cancer but it shielded the important p53 gene, a gene that works to prevent cancer.

"As soon as our skin becomes sun damaged, the p53 gene goes to work repairing that damage and thereby preventing skin cancer occurring.

"But over time if skin is burnt regularly the p53 gene mutates and can no longer do the job it was intended for -- it no longer repairs sun damaged skin and without this protection skin cancers are far more likely to occur."

The study, published in the Pigment Cell & Melanoma Research journal, looked at the impact of sunlight on human skin, both with and without sunscreen, and found no evidence of UV-induced skin damage when proper application of sunscreen (SPF30+) had been applied to exposed area.

"Melanoma is the most lethal form of skin cancer with research showing damage of melanocytes -- the pigment-producing cells of the skin -- after sun exposure plays a role in the development of skin cancer," Dr Hacker said.

Dr Hacker said the study, funded by Cancer Council Queensland, involved 57 people undergoing a series of skin biopsies to determine molecular changes to the skin before and after UV exposure and with and without sunscreen.

Original post:
Sunscreen saves superhero gene

Recommendation and review posted by Bethany Smith

Newswise LOS ANGELES (Oct. 8, 2013) Julie Miller is a key part of an extensive effort at Cedars-Sinai to increase awareness of and support for womens cancer research. She not only has registered to participate in clinical research, but shes also lacing up her running shoes.

Miller, who lives in Westwood, Calif., is a participant in both Research for Her and the Run for Her 5K Run and Friendship Walk.

Millers journey started more than four years ago when she made an appointment with Ora Karp Gordon, MD, director of the Cedars-Sinai GenRISK Adult Genetics Program, to learn if she may be a carrier of the BRCA gene, a genetic mutation that greatly increased her risk of developing breast and ovarian cancers. With a long lineage of family members diagnosed with these cancers, the odds were stacked against her, and Miller soon learned that she too was a carrier.

With this knowledge, Miller made a proactive decision to dramatically lessen her chances of developing cancer by undergoing prophylactic surgeries to remove her breasts, ovaries and fallopian tubes. Her experience prompted Miller to become an advocate for not only herself, but womens cancer research and awareness.

This commitment also led Miller to participate in the new Research for Her program at the Samuel Oschin Comprehensive Cancer Institute. The program is aimed at increasing womens representation in medical research and intended to help scientists understand how cancers develop and how treatments affect people.

Research for Her is the research arm of a Cedars-Sinai commitment to increasing treatment options and public awareness of womens cancers. Research for Her is supported by Run for Her, the annual 5K run and friendship walk.

In 2005, the inaugural Run for Her event took place in a Cedars-Sinai parking lot with 700 people. Since then, thousands of individuals have joined the cause to help increase ovarian cancer awareness. Miller will be participating in this years event Sunday, Nov. 10, 2013.

Run for Her began when Kelli Sargent created a marketing and operations plan for an ovarian cancer 5k run/walk for her master's degree thesis. She later partnered with the Cedars-Sinai Womens Cancer Program at the Samuel Oschin Comprehensive Cancer Institute to create the event. Sargents passion for the event stemmed from her mothers eight-year battle with ovarian cancer, a battle she lost in 2008.

Run for Her supports more than vital funds for ovarian cancer research and awareness, Sargent said. It provides an outlet for people to share their experiences, cry and laugh. Its a day to remember the loved ones we lost to this disease and continue fighting for those whose battle continues.

Both research-driven programs are providing women an empowering opportunity to change the landscape of womens cancer.

Follow this link:
Ovarian Cancer Research and Awareness Remain a Focus at Cedars-Sinai

Recommendation and review posted by Bethany Smith

8 October 2013 | Talks | By: M@

London Science Festival returns on 23-30 October, with a constellation of scientific talks, walks and happenings. This time round, the main theme is engineering, with Brunel himself as the mascot. Theres also an underlying science-in-London theme, and many local institutions have partnered with the Festival. Weve distilled this bubbling admixture into manageable aliquots below:

The Festivals launch event sees an evening of engineering, fun, music and cocktails down in the Brunel Museums Grand Entrance Hall, one of the Victorian portals that once led into the Thames Tunnel. Engineers from The Shard and Crossrail will also be on hand to talk engineering. 20, prebook, 6.30-11pm

Launch event for a new digital graphic novel thattells the history of DNA from the perspective of a 500 year old man kept alive by genetic therapy. The story is told on touch-screen interfaces, on show at GV Art Gallery on Chiltern Street. Free, prebook, 6-9pm. You can then pop along without booking during opening hours until 30 October

Sure to be a popular event, pharmacologists Atholl Johnston, Kim Wolff and Ian Stolerman discuss the uses of poisons and drugs in the Sherlock Holmes stories. Better yet, the event takes place in the same hospital where Holmes is first encountered in A Study in Scarlet: St Barts Pathology Museum. 10.30, prebook, 6pm

Another chance to tour the recently reopened sections of the Olympic Park, with a particular emphasis on the engineering behind the buildings and site. 10, prebook, 11am-1pm

Alfred Russell Wallace arrived at the idea of evolution by natural selection around the same time as Charles Darwin, but is less well known. 100 years after his death, the Linnean Society (Piccadilly) host a family-oriented event exploring the ideas of Wallace. Nice building, too. Free, prebook, 11am-noon

Inspired by our own scientific pub crawl, London Science Festival invites you on a circuit of London pubs with scientific connections. Start at the Sir Alexander Fleming in Paddington, and we might well see you there. 10 (including first drink), prebook, 4-8pm

Sit in on a series of four talks about science and engineering at Brunel University, Uxbridge. Topics include aerodynamics, biomimetics, the Large Hadron Collider and climate change. 10, prebook, 6-8pm

Uwe Krueger discusses how engineers can use imagination to shape the future and tackle the big problems of the modern age, such as climate change. The event takes place at the Royal Academy of Engineering in St James. Free, prebook, 6.30-8pm

Continued here:
London Science Festival Returns With Engineering Focus

Recommendation and review posted by Bethany Smith

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, October 8, 2013Job applicants try to make a good impression when meeting a prospective employer, but employers may be able to learn what applicants are really like by screening their social media posts. Unfiltered personal communications, photos, comments about others, and references to alcohol and drug use reflect five revealing personality characteristics that might impact their work performance, according to an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cyberpsychology, Behavior, and Social Networking website.

The article "Big Five Personality Traits Reflected in Job Applicants' Social Media Postings," identifies links between online behavior and extraversion, agreeableness, conscientiousness, emotional stability, and openness to experience, according to authors J. William Stoughton, MS, Lori Foster Thompson, PhD, and Adam Meade, PhD, North Carolina State University, Raleigh.

"Becoming aware that employment screening is being enhanced by information provided on social media platforms such as Twitter and Facebook may affect individuals' choices of current posts by causing them to reflect on future consequences" says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's over 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Visit link:
5 personality traits employers should look for in a job applicant's social media content

Recommendation and review posted by Bethany Smith

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Sarah Smith sas2072@med.cornell.edu 646-317-7401 Weill Cornell Medical College

NEW YORK (October 8, 2013) -- Damaged or diseased organs may someday be healed with an injection of blood vessel cells, eliminating the need for donated organs and transplants, according to scientists at Weill Cornell Medical College.

In studies appearing in recent issues of Stem Cell Journal and Developmental Cell, the researchers show that endothelial cells -- the cells that make up the structure of blood vessels -- are powerful biological machines that drive regeneration in organ tissues by releasing beneficial, organ-specific molecules.

They discovered this by decoding the entirety of active genes in endothelial cells, revealing hundreds of known genes that had never been associated with these cells. The researchers also found that organs dictate the structure and function of their own blood vessels, including the repair molecules they secrete.

Together, the studies show that endothelial cells and the organs they are transplanted into work together to repair damage and restore function, says the study's lead investigator, Shahin Rafii, M.D., a professor of genetic medicine and co-director of the medical college's Ansary Stem Cell Institute and Tri-SCI Stem Center. When an organ is injured, its blood vessels may not be able to repair the damage on their own because they may themselves be harmed or inflamed, says Dr. Rafii, who is also an investigator at the Howard Hughes Medical Institute.

"Our work suggests that that an infusion of engineered endothelial cells could engraft into injured tissue and acquire the capacity to repair the organ," he says. "These studies -- along with the first molecular atlas of organ-specific blood vessel cells reported in the Developmental Cell paper-- will open up a whole new chapter in translational vascular medicine and will have major therapeutic application.

"Scientists had thought blood vessels in each organ are the same, that they exist to deliver oxygen and nutrients. But they are very different," and each organ is endowed with blood vessels with unique shape and function and delegated with the difficult task of complying with the metabolic demands of that organ, Dr. Rafii adds.

Creating an endothelial cell genetic 'atlas'

In the Developmental Cell study, the research team examined nine different tissues at homeostasis -- a steady, healthy state -- as well as liver and bone marrow recovering from a traumatic injury.

Read the rest here:
Blood vessel cells can repair, regenerate organs, say Weill Cornell scientists

Recommendation and review posted by Bethany Smith

I recently attended a symposium concerning the effect that new genetic testing can have on the medical care that you receive. This isnt five or ten years down the road but it is taking place today.

Just from a blood sample, your approximately 23,000 genes can be tested for gene mutations that cause diseases such as cancer, heart disease, intellectual and physical disabilities, and the list goes on and on. For example, why do some individuals have a strong family history of developing certain types of cancers? Tests called Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS), can determine if there is a mutation in certain cancer causing genes that can be passed on to family members. These tests can also provide good news by determining that an individual does not have the gene causing cancer.

Then there is Personalized Medicine.

Why is it that when 100 patients have the same disease and are treated with the same medication, a certain percentage will not respond to the treatment or will develop a serious reaction to the medication? Many times it is due to the individuals genetic make-up. By knowing that patients will not respond to certain medications because of their gene make-up, a more effective drug can be found to successfully treat the illness.

Recent reports have shown that, taking a blood sample from a pregnant woman, a tremendous amount of genetic information can be uncovered about the fetus. Blood from pregnant women contain fetal blood cells. By examining these fetal cells, the genome of the fetus can be ascertained. With this information it can then be determined if the fetus has mutated genes for certain treatable genetic diseases such as breast, ovarian, and thyroid cancers, certain heart diseases and familial high cholesterol.

For some people this is too much information and they may opt out of having such tests. Also, these tests are not a panacea. There can be problems. For example, at times the significance of some of the mutated genes discovered may not be known but may have the potential to be associated with some type of disease. Do you share this uncertain incidental finding with the patient?

We are entering into a new era of medicinegenomic medicinethat is filled with optimism but also has a great deal of uncertainty.

See the original post:
Dr. Murray Feingold: Genetic testing

Recommendation and review posted by Bethany Smith

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: George Hunka ghunka@aftau.org 212-742-9070 American Friends of Tel Aviv University

Until now, understanding and using genetic information has depended on the scientists and doctors who do the testing. No longer.

Now, software developed by researchers at Tel Aviv University is putting the power of genetic information in the hands of the people. GeneG, a smartphone app and associated web site created by Dr. Noam Shomron at TAU's Faculty of Medicine allows individuals to access and analyze their genome at any time. After undergoing whole genome sequencing, users can upload their data to the GeneG website for analysis. The results are available via the GeneG app on mobile devices.

"For the first time you can take your genome home and look at it whenever you want," says Shomron. "We are giving you eyes to peer into your genetics." And as new analytical tests are developed, you can apply them right away.

TAU graduate students Ofer Isakov and Gershon Celniker worked under Shomron to develop the software, which is to be released to physicians in October ahead of a public release. More information about the project can be found at http://www.geneg.org/.

Data-driven demand

The first map of the human genome, published in 2003, took eight years of work by thousands of researchers and cost $1 billion. Today, people can get their entire genome sequenced within a few weeks for around $1,000. Thousands have had it done, and the turnaround time and cost are fast decreasing as the technology advances. GeneG aims to meet the growing demand for ways to make sense of all this information.

At the moment, DNA sequencing focuses on specific areas, looking for quirks in sequences within individual genes, clusters of genes, or chromosomes. A downside of this targeted approach is that each genetic test requires donating new DNA and waiting for it to be processed. Shomron gives the example of a woman who wants to get tested before becoming pregnant. Currently, she has to take a day off work, travel to a lab to have her blood drawn, then wait for several weeks while a selection of her genes is amplified and sequenced. If she later decides to conceive again and wants the newest genetic tests, she has to start the whole process over again.

With GeneG, on the other hand, new tests are just a software update away. Users who have uploaded their genomes to the website can "query" them using digital genetic tests based on research from organizations like the National Institutes of Health, Stanford University, and the European Bioinformatics Institute. The software provides all the functions of more limited genetic testing, including diagnosing and predicting genetic diseases, checking potential parents for genetic traits that could cause disease in their future children, and screening unborn and newborn babies. And it can all be done without setting foot in a lab.

View post:
Smartphone app brings genetic analysis to the palm of your hand

Recommendation and review posted by Bethany Smith

Genetics - Supper #39;s Ready (Parte 4) @ Teatro Coliseo, Bs As, 21/09/13.
Genetics - Supper #39;s Ready (Parte 4) (Foxtrot, 1972). Teatro Coliseo, Bs As, Argentina. Sábado 21 de Septiembre de 2013. HD Stereo.

By: Gino Zolezzi

Follow this link:
Genetics - Supper's Ready (Parte 4) @ Teatro Coliseo, Bs As, 21/09/13. - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 30
My Sims 3 Page: http://mypage.thesims3.com/mypage/Llandros2012 My Blog: http://Llandros09.blogspot.com My Facebook: https://www.facebook.com/Llandros09?ref=t...

By: Llandros09

See the rest here:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 30 - Video

Recommendation and review posted by Bethany Smith

SB Education Days 2013 - Genetics
Genetics John Carey, MD Janice Palumbos, MS, CGC.

By: meilanik

View original post here:
SB Education Days 2013 - Genetics - Video

Recommendation and review posted by Bethany Smith

vT Genetics - MW3 Game Clip
Game Clip.

By: ChromeToYahDome

Continue reading here:
vT Genetics - MW3 Game Clip - Video

Recommendation and review posted by Bethany Smith

While the vast majority of graduate degrees will give you an edge, not all are created equal and some More The 10 most useless graduate degrees

The Cadillac Escalade has never lacked for attention. Launched as a rush response to the Lincoln Navigator's More Cadillac reveals the 2015 Escalade, its blingiest land yacht yet

Howard Schultz, Starbucks Corp's outspoken CEO, on Monday urged fellow business leaders to ratchet up More Starbucks founder urges CEOs to push for end to federal shutdown

New shopping services will allow consumers to instantly buy items they see on television, in magazines More New experiment could take consumer impulsiveness to new heights

October 7 marks the date the Motion Picture... More The highest grossing R-rated films of all time

Neverfull - the name of Louis Vuitton's best-selling handbag - sums up well its parent LVMH: even if More Brand-hungry LVMH seeks new niche as Vuitton flags

Since April, when Facebook bought the photo-sharing social network, Instagram's user base has grown from More Instagram will have ads. Get over it

Much has been written about how Twitter Inc. wants to avoid the fate of Facebook Inc., which saw its More Where Twitter is better than Facebook

The U.S. is overtaking Russia as the world's largest producer of oil and natural gas, a startling shift More U.S. is overtaking Russia as largest oil and gas producer

McDonald's took on Chipotle as a subsidiary in 1998 and largely financed the chain's rapid expansion More Chipotle founder completely disses former parent company McDonald's

See original here:
Block & Leviton LLP Investigates Atossa Genetics, Inc. for Possible Violations of the Federal Securities Laws

Recommendation and review posted by Bethany Smith

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky is investigating potential claims on behalf of purchasers of Atossa Genetics, Inc. (Atossa or the Company) (ATOS) securities concerning possible violations of securities laws.

For more information, click here: http://zlk.9nl.com/atossa-genetics-atos.

On October 4, 2013, Atossa announced a voluntary recall (the recall) of its ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test (MASCT), including the recall of the MASCT System Kit and Patient Sample Kit. The recall commenced to address concerns raised in a February 2013 warning letter issued by the U.S. Food and Drug Administration (the FDA), in which the FDA raised concerns regarding the current instructions for use (IFU), certain promotional claims used to market these devices, and regarding the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU.

If you own Atossa stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/atossa-genetics-atos.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

See original here:
ATOSSA GENETICS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Claims ...

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability, today announced that new data further supporting their robust platform validation and the clinical value of the GoodStart SelectTM carrier screening test will be presented during two poster sessions at the 2013 American Society for Reproductive Medicine Annual Meeting taking place October 12 17 in Boston.

The schedule for presentations by Good Start Genetics is as follows:

Date & Time: Tuesday, October 15, 2013 from 7:00 8:45 a.m. Title: A RIGOROUS PROCESS FOR SELECTING AN OPTIMAL MUTATION SET FOR POPULATION-BASED CARRIER SCREENING Program Number: P018 Session ID: P-149

Date & Time: Thursday, October 17, 2013 from 7:00 8:45 a.m. Title: CARRIER SCREENING OF 8,500 IVF PATIENTS UTILIZING NEXT GENERATION DNA SEQUENCING DETECTS COMMON, RARE AND OTHERWISE UNDETECTABLE MUTATIONS ACROSS SOCIETY-RECOMMENDED DISEASES Program Number: P048 Session ID: P-1151

About GoodStart Select

GoodStart Select is Good Start Genetics menu of carrier screening tests that, for diseases such as cystic fibrosis, detects many more disease-causing mutations than any other routine carrier screening test, regardless of patient ethnicity. After years of development and rigorous validation, Good Start Genetics has harnessed the power of its sophisticated technologies, including next-generation DNA sequencing (NGS), to provide highly accurate and actionable tests resulting in higher mutation detection rates and fewer missed carriers. Good Start offers genetic screening tests for all disorders recommended by the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG), and leading Jewish advocacy groups.

To support the companys gold standard genetic screening capabilities, Good Start has a dedicated team of customer care specialists, board certified medical geneticists and genetic counselors who provide step-by-step support, from test selection through results, analysis and reporting. For these reasons, reproductive health specialists and their patients can have the highest degree of confidence in their genetic carrier screening results.

About Good Start Genetics, Inc.

Good Start Genetics is an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability combined with other technologies to deliver best-in-class tests for routine genetic screening. Through its GoodStart Select offering, the company provides the most comprehensive and clinically actionable set of tests for known and novel mutations that cause inherited diseases. Good Starts NGS capabilities can be applied to multiple disease areas, including pre-conception carrier screening in the in-vitro fertilization setting. For more information, please visit http://www.goodstartgenetics.com.

Originally posted here:
Good Start Genetics to Present Clinical Data at 2013 American Society for Reproductive Medicine Annual Meeting

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, today announced its vice president of R&D, Jane Houldsworth, Ph.D., will provide the opening keynote presentation for the "Realizing the Potential of Precision Medicine" conference on October 9, 2013 at 1:00 pm ET.

"The use of genetic information to improve diagnosis, treatment and patient outcomes is the very foundation of precision medicine," stated Panna Sharma, CEO of CGI. "This conference brings together key industry thought leaders to provide attendees with insights on how to apply precision medicine in the clinical setting. Participating companies include major players in genetics, such as Illumina and Luminex. Other participants include Weill Cornell Medical College, New-York Presbyterian Hospital and other key institutions that serve the needs of oncology patients. For CGI to have the honor of opening this conference is a testament to our leadership position in the rapidly evolving field of precision medicine."

Dr. Houldsworth's keynote "From Vision to Reality, the Cancer Genetics Complete Experience," will use CGI's Complete Programs(TM) as a case study to strategize the introduction and successful licensure of molecular and biomarker based diagnostic testing. Her keynote will also address preparation for constant upgrading and expansion to include novel findings and methodological advances.

Dr. Houldsworth has over 20 years of experience in translational research and has published more than 50 peer-reviewed papers and 15 chapters. Since her joining CGI in 2007, Dr. Houldsworth has successfully led the clinical validations and licensures of CGI's proprietary products including MatBA(R) and UroGenRA(TM).

The conference, "Realizing the Potential of Precision Medicine," will take place at the AMA Conference Center in New York City, October 9 to October 11, 2013. Registration can be done at http://goo.gl/aHOxff. The conference is suited for executives and health care professionals representing academic medical centers, community hospitals, and hospital and health networks, and the event should provide networking and deal-making opportunities.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Read this article:
Cancer Genetics, Inc. Will Open Precision Medicine Conference With Keynote Presentation

Recommendation and review posted by Bethany Smith

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Karen Mallet km463@georgetown.edu Georgetown University Medical Center

WASHINGTON A team of researchers at Georgetown University Medical Center (GUMC) has found that loss of an anti-aging gene induces retinal degeneration in mice and might contribute to age-related macular degeneration, the major cause of blindness in the elderly.

In the Oct. 9 issue of the Journal of Neuroscience, the scientists demonstrated a key role for the aging-suppressor gene Klotho in maintaining the health of the mouse and human retina. They say that in their animal studies, loss of Klotho expression leads to characteristics observed in both kinds of macular degeneration wet and dry seen in humans.

Klotho, a hormone that is synthesized and secreted by some organs and tissues, is being studied worldwide for its anti-aging properties. A Japanese researcher discovered 15 years ago that when Klotho is mutated, a mouse that should live two years survives for only two months. Transgenic mice that overexpress the Klotho gene have a longer-than-expected lifespan.

"We found four important functions Klotho provides in the human retina, which leads us to believe that the gene is crucial to the health of this light sensitive tissue," says the study's senior investigator, Nady Golestaneh, PhD, assistant professor of ophthalmology, neurology, biochemistry and molecular & cellular biology at GUMC.

They found that Klotho increases the activity of genes that synthesize the light absorbing visual pigments in the retinal cells. Klotho also increases the expression of genes that protect against the oxidative stress known to damage the retina, and which can lead to dry macular degeneration. Klotho inhibits the vascular endothelial growth factor and therefore, might play an important role in inhibiting the overgrowth of blood vessels in the eye, a major cause of wet macular degeneration.

Klotho also regulates phagocytosis of the outer segment of photoreceptors in the retina. This process allows the photoreceptors to renew themselves, and if that function is abolished, the photoreceptors degenerate and die causing blindness.

"For these reasons, we believe Klotho might be an interesting therapeutic target for age-related macular degeneration," Golestaneh says. "Gene therapy or cell therapy might be able to induce new expression of Klotho in the aging retina."

But she adds that before these strategies can be tested, research that quantifies the decline of Klotho expression in human eyes, and directly links this dysfunction to macular degeneration, must be undertaken.

See original here:
Loss of anti-aging gene possible culprit in age-related macular degeneration

Recommendation and review posted by Bethany Smith

Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months
This video is from YouTube Channel-wilsonho ho. In his YouTube Wilson never mentions much. Just a short message, My grandmother is healthy now after 8months ...

By: Purtier Placenta Singapore Original

More:
Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months - Video

Recommendation and review posted by simmons

Brad discusses his combination cell therapy for his arthritic knee
20 months after his bone marrow aspirate concentrate and adipose injection into his arthritic knee, Brad discusses his result. Dr Adelson practices in Park C...

By: Harry Adelson

Go here to see the original:
Brad discusses his combination cell therapy for his arthritic knee - Video

Recommendation and review posted by Bethany Smith